• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Second Sight Medical Products Inc. (Amendment)

    7/22/22 5:06:56 PM ET
    $EYES
    Industrial Specialties
    Health Care
    Get the next $EYES alert in real time by email
    SC 13D/A 1 g083099_sc13d.htm SC 13D/A

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 8)*

     

    Second Sight Medical Products, Inc.

    (Name of Issuer)

     

    Common Stock, no par value

    (Title of Class of Securities)

     

    81362J100

    (CUSIP Number)

     

    13170 Telfair Avenue

    Sylmar, CA 91342

    (818) 833-5000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    May 18, 2022

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 81362J100   13D   Page 2 of 4 Pages
             
    1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Gregg Williams
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
       
    3.   SEC USE ONLY
     
       
    4.   SOURCE OF FUNDS (see instructions)
     
    00
       
    5.   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ☐    
    6.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      7.   SOLE VOTING POWER
     
    17,292,679 (1)
      8.   SHARED VOTING POWER
     
    00,000
      9.   SOLE DISPOSITIVE POWER
     
    17,293,679 (1)
      10.   SHARED DISPOSITIVE POWER
     
    00,000
    11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    17,292,6799 (1)
       
    12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
       
    13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    38.06% (2)
       
    14.   TYPE OF REPORTING PERSON (see instructions)

    IN
       
             
       

    (1)   Includes  (i) 4,859,893 shares of common stock and warrants to purchase 1,713,599 shares of common stock owned by GW Trust, (ii) 3,638,568 shares of common stock and warrants to purchase 3,453,038 shares of common stock owned by Williams International Co. LLC (iii) 544,760 shares of common stock owned by Sam Williams Family Investments LLC and (iv) 2,193,926 shares of common stock and warrants to purchase 863,259 shares of common stock owned by Sam B. Williams 1995 Generation-Skipping Trust. Includes 25,636 shares of common stock issuable to Mr. Williams upon exercise of options. Greg Williams has voting and dispositive power over all of these shares.

    (2)   Beneficial ownership is based on 39,409,176 shares of common stock after giving effect to (i) 39,409,176 shares of common stock outstanding and (ii) warrants currently exercisable to purchase 6,029,896 shares of common stock.

       

     

     

     

     

    CUSIP No. 81362J100   13D   Page 3 of 4 Pages
             
    1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Gregg Williams 2006 Trust
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
       
    3.   SEC USE ONLY
     
       
    4.   SOURCE OF FUNDS (see instructions)
     
    PF
       
    5.   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ☐    
    6.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Michigan
       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      7.   SOLE VOTING POWER
     
    6,573,492 (3)
      8.   SHARED VOTING POWER
     
    00,000
      9.   SOLE DISPOSITIVE POWER
     
    6,573,492 (3)
      10.   SHARED DISPOSITIVE POWER
     
    00,000
    11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,573,492 (3)
       
    12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
       
    13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    14.47% (4)
       
    14.   TYPE OF REPORTING PERSON (see instructions)

    OO
       
             
       

    (3)   Shares beneficially owned includes (i) 4,859,893 shares of common stock and (ii) warrants to purchase 1,713,599 shares of common stock. Mr. Williams has sole voting and dispositive power for shares held by this Reporting Person.

    (4)   Beneficial ownership is based on upon shares of common stock as set forth in footnote 2 above.

       

     

     

     

     

    CUSIP No. 81362J100   13D   Page 4 of 4 Pages
             
    1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Sam Williams Family Investments, LLC
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
       
    3.   SEC USE ONLY
     
       
    4.   SOURCE OF FUNDS (see instructions)
     
    PF
       
    5.   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ☐    
    6.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Michigan
       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      7.   SOLE VOTING POWER
     
    544,760 (5)
      8.   SHARED VOTING POWER
     
    00,000
      9.   SOLE DISPOSITIVE POWER
     
    544,760 (5)
      10.   SHARED DISPOSITIVE POWER
     
    00,000
    11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    544,760 (5)
       
    12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
       
    13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    1.2% (6)
       
    14.   TYPE OF REPORTING PERSON (see instructions)

    CO
       
             
       

    (5)   Shares beneficially owned includes 544,760 shares of common stock. Mr. Williams has sole voting and dispositive power for shares held by this Reporting Person.

    (6)   Beneficial ownership is based on upon shares of common stock as set forth in footnote 2 above.

       

     

     

     

     

    CUSIP No. 81362J100        
             
    1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Williams International Co. LLC
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
       
    3.   SEC USE ONLY
     
       
    4.   SOURCE OF FUNDS (see instructions)
     
    PF
       
    5.   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ☐    
    6.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Michigan
       

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

      7.   SOLE VOTING POWER
     
    7,091,606 (7)
      8.   SHARED VOTING POWER
     
    00,000
      9.   SOLE DISPOSITIVE POWER
     
    7,091,606 (7)
      10.   SHARED DISPOSITIVE POWER
     
    00,000
    11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,091,606 (7)
       
    12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
       
    13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    15.61% (8)
       
    14.   TYPE OF REPORTING PERSON (see instructions)

    CO
       
             
       

    (7)   Shares beneficially owned includes (i) 3,638,568 shares of common stock, (ii) 3,453,038 warrants to purchase shares of common stock. Mr. Williams has sole voting and dispositive power for shares held by this Reporting Person.

    (8)   Beneficial ownership is based on upon shares of common stock as set forth in footnote 2 above.

       

     

     

     

     

    CUSIP No. 81362J100        
             
    1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Sam B. Williams 1995 Generation Skipping Trust
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
       
    3.   SEC USE ONLY
     
       
    4.   SOURCE OF FUNDS (see instructions)
     
    PF
       
    5.   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ☐    
    6.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Michigan
       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      7.   SOLE VOTING POWER
     
    3,057,185 (9)
      8.   SHARED VOTING POWER
     
    00,000
      9.   SOLE DISPOSITIVE POWER
     
    3,057,185 (9)
      10.   SHARED DISPOSITIVE POWER
     
    00,000
    11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,057,185 (9)
       
    12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
       
    13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.73% (10)
       
    14.   TYPE OF REPORTING PERSON (see instructions)

    CO
       
             
       

    (9)   Shares beneficially owned includes (i) 2,193,926 shares of common stock, (ii) 863,259 warrants to purchase shares of common stock. Mr. Williams has sole voting and dispositive power for shares held by this Reporting Person.

    (10) Beneficial ownership is based on upon shares of common stock as set forth in footnote 2 above.

       

     

     

     

     

    Explanatory Note:  Gregg G. Williams 2006 Trust, of which Gregg G. Williams is trustee (“Purchaser”), acquired an aggregate of 1,026,085 shares of common stock of the Issuer respectively in open market purchases in multiple transactions between May 18, 2022 and June 14, 2022, as set forth on Schedule A attached hereto, at prices ranging from$1.47 for an aggregate purchase amount of approximately $2.00, inclusive of brokerage commissions.

     

    This Amendment No. 8 amends the Schedule 13D, as previously amended and filed on August 29, 2019, as specifically set forth herein.

     

    Item 1.  Security and Issuer.

     

    This statement on Schedule 13D relates to the common stock, no par value (the “Common Stock”), of Second Sight Medical Products Inc., a California corporation (the “Issuer”). The principal executive offices of the Issuer are located at 13170 Telfair Avenue, Sylmar, CA 91342.

     

    The Reporting Persons (as defined below) beneficially own 17,292,679 shares of Common Stock (the “Shares”), which includes: (i) 11,237,147 shares of Common Stock, (ii) currently exercisable warrants to purchase 6,029,896 shares of common stock and (iii) and option to purchase 25,636 shares of common stock.

     

    The Shares represent beneficial ownership of approximately 37.3% of the outstanding shares of Common Stock. See footnote 2 above.

     

    Item 2.  Identity and Background.

     

    (a), (f) This statement is being filed by:

     

    (i) Gregg Williams, an individual;

     

    (ii) Gregg G. Williams 2006 Trust, a trust (“Williams Trust”);

     

    (iii) Sam Williams Family Investments LLC, a Michigan limited liability company (“Williams LLC”);

     

    (iv) Williams International Co. LLC, a Michigan limited liability company (“Williams International”); and

     

    (v) Sam B. Williams 1995 Generation-Skipping Trust (“GST” and together with Mr. Williams, the Williams Trust, Williams LLC, and Williams International, the “Reporting Persons”)

     

     

     

     

     (b) The address of the principal business and principal office of each of the Reporting Persons is 13170 Telfair Avenue, Sylmar Ca 91342.

     

    (c) Mr. Williams has been the Chief Executive Officer at Williams International, a leading developer and manufacturer of small gas turbine engines, since April 2005, and has been a member of the Board of Directors of the Issuer since June 2009.

     

    (d), (e) During the last five years, none of the Reporting Persons (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

     

    (f) Mr. Williams is a citizen of the United States.

     

    Item 3.  Source or Amount of Funds or Other Consideration.

     

     The Shares were acquired with the personal funds of the Reporting Persons.

     

    Item 4.  Purpose of Transaction.

     

    The Reporting Persons, directly or indirectly through certain affiliates, acquired the shares of the Issuer for investment purposes.. Nevertheless, as a result of his appointment in March 2018 as the non-executive Chairman of the Board of Directors and his beneficial share ownership of approximately 38.06% of the Common Stock, Mr. Williams is deemed to control the Issuer. Mr. Williams has at all times from immediately prior to and since the initial public offering of the Common Stock in November 2014 been a principal shareholder and director of the Issuer and is a member of the family which co-founded the Issuer.  

     

    The Reporting Persons will continue to evaluate their ownership, investment and voting position in the Issuer and they currently expect to continue holding Issuer’s securities for investment. Moreover, they may acquire additional securities of the Issuer, upon terms which they consider to be favorable, in open market and in privately-negotiated transactions.

     

    Item 5.  Interest in Securities of the Issuer.

     

     (a)(i) Gregg Williams is the beneficial owner of an aggregate of 17,292,679 or 38.06% of the Issuer’s outstanding shares of Common Stock, including currently exercisable warrants to purchase 6,029,896 shares of common stock.

     

    (ii) Gregg G. Williams 2006 Trust is the beneficial owner of an aggregate of 6,573,492 or 14.47% of the Issuer’s shares, including currently exercisable warrants to purchase 1,713,599 shares of Common Stock.

     

    (iii) Sam Williams Family Investments LLC is the beneficial owner of an aggregate 544,760 or 1.20% of the Issuer’s shares.

     

    (iv) Williams International Co. LLC is the beneficial owner of an aggregate 7,091,606 or 15.61% of the Issuer’s shares, including currently exercisable warrants to purchase 3,453,038 shares of Common Stock.

     

    (v) GST is the beneficial owner of an aggregate 3,057,185 or 6.73% of the Issuer’s shares, including currently exercisable warrants to purchase 863,259 shares of Common Stock.

     

    (b) Mr. Williams has power to vote or direct the vote and sole power to dispose or direct the disposition of the shares and warrants owned by the Reporting Persons.

     

     

     

     

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

     None 

     

    Item 7.  Material to Be Filed as Exhibits.

     

    None

     

     

     

     

    SIGNATURE

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

    Date: July 22, 2022  
      /s/Gregg Williams
      Gregg Williams
       
      GREGG WILLIAMS 2006 TRUST
       
    Date: July 22, 2022 /s/Gregg Williams
      By: Gregg Williams
      Its: Trustee
       
      SAM WILLIAMS FAMILY INVESTMENTS LLC
       
    Date: July 22, 2022 /s/Gregg Williams 
      By: Gregg Williams
      Its: Manager
       
      WILLIAMS INTERNATIONAL CO. LLC
       
    Date: July 22 2022 /s/Gregg Williams 
      By: Gregg Williams
      Its: Manager
       
      SAM B WILLIAMS 1995 GENERATION-SKIPPING TRUST
       
    Date: July 22, 2022 /s/Gregg Williams
      By: Gregg Williams
      Its: Trustee

     

     

    Get the next $EYES alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EYES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)

    Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ:VANI) (the "Company" or "Vivani") announced that trading of the Company's common stock on The Nasdaq Capital Market under the symbol "VANI" will commence today. Vivani is the combination of Nano Precision Medical, Inc. ("NPM") and Second Sight Medical Products, Inc. Closing of the merger was completed and announced yesterday, August 30, 2022. Vivani leverages proprietary technologies to develop and commercialize drug and device implants that treat patients with chronic diseases with high unmet medical need. Vivani has approximately $55 million in cash to advance the development of its portfolio, which includes lead asset N

    8/31/22 6:00:00 AM ET
    $EYES
    Industrial Specialties
    Health Care

    Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

    Vivani will be traded under the new ticker (NASDAQ:VANI) Second Sight Medical Products, Inc.(NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today the completion of its merger with Nano Precision Medical, Inc. ("NPM"). NPM is a biopharmaceutical business which develops miniaturized, subdermal drug implants utilizing its proprietary NanoPortal™ technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. In connection with the merger, Second Sight changed its name to Vivani Medical, Inc

    8/30/22 6:00:00 AM ET
    $EYES
    Industrial Specialties
    Health Care

    Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting

    Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. At the annual meeting, the shareholders voted on seven proposals: (1) approving the merger agreement with Nano Precision Medical, Inc. ("NPM") and the transactions contemplat

    7/29/22 6:00:00 AM ET
    $EYES
    Industrial Specialties
    Health Care

    $EYES
    SEC Filings

    View All

    Second Sight Medical Products Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vivani Medical, Inc. (0001266806) (Filer)

    1/6/23 4:04:18 PM ET
    $EYES
    Industrial Specialties
    Health Care

    Second Sight Medical Products Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vivani Medical, Inc. (0001266806) (Filer)

    12/15/22 4:45:35 PM ET
    $EYES
    Industrial Specialties
    Health Care

    Second Sight Medical Products Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Vivani Medical, Inc. (0001266806) (Filer)

    11/28/22 5:29:22 PM ET
    $EYES
    Industrial Specialties
    Health Care

    $EYES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Mendelsohn Adam

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/23/23 9:13:06 PM ET
    $EYES
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Makes Brigid

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/23/23 9:11:40 PM ET
    $EYES
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Dwyer Donald

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/23/23 9:09:48 PM ET
    $EYES
    Industrial Specialties
    Health Care

    $EYES
    Leadership Updates

    Live Leadership Updates

    View All

    Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting

    Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. At the annual meeting, the shareholders voted on seven proposals: (1) approving the merger agreement with Nano Precision Medical, Inc. ("NPM") and the transactions contemplat

    7/29/22 6:00:00 AM ET
    $EYES
    Industrial Specialties
    Health Care

    Second Sight Medical Products Announces Results of its 2021 Annual Meeting

    Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held May 28, 2021. Second Sight held its annual meeting online due to the COVID-19 pandemic. 60.98% of shareholders were present online or by proxy. Shareholders voted on four proposals: (1) electing six (6) members of the Board of Directors, to serve until the next annual meeting of shareholders in 2022 and until their successors are duly elected and qualified, (2) ratifying the appointment of Gumbiner Savett Inc. as our

    6/1/21 6:00:00 AM ET
    $EYES
    Industrial Specialties
    Health Care

    Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market

    Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market Aims to create a global leader with potential to treat nearly all forms of blindnessCombined company to trade on Nasdaq and benefit from business and development synergies in the U.S. and EuropeTransaction provides broader access to financing sources to enable the combined company to accelerate the development and commercialization of its productsPixium Vision to remain listed on Euronext Growth and to be the largest shareholder of the new combined company listed on NasdaqTransaction expected to close in late Q1 or the beginning of Q2 2021Conference Call s

    1/6/21 12:00:00 AM ET
    $EYES
    Industrial Specialties
    Health Care

    $EYES
    Financials

    Live finance-specific insights

    View All

    Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company

    Nano Precision Medical's lead program (NPM-119) is a tiny subdermal implant of a GLP-1 receptor agonist to treat patients with Type 2 diabetes Second Sight will issue 134M shares to acquire full ownership of Nano Precision Medical. Second Sight shareholders will own ~23% of the combined company. Second Sight shareholders join NPM shareholders, including AstraZeneca which has been a strategic investor since 2016 Second Sight currently has over $69M to enable the advancement of NPM-119 through clinical proof of concept into a pivotal clinical trial and continued exploration of the visual prosthesis business opportunity Investor Conference Call Scheduled for Tuesday, February 8, 2022,

    2/7/22 4:30:00 PM ET
    $EYES
    Industrial Specialties
    Health Care

    $EYES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Second Sight Medical Products Inc. (Amendment)

    SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

    9/1/22 9:34:58 PM ET
    $EYES
    Industrial Specialties
    Health Care

    SEC Form SC 13D filed by Second Sight Medical Products Inc.

    SC 13D - Vivani Medical, Inc. (0001266806) (Subject)

    8/31/22 6:49:04 PM ET
    $EYES
    Industrial Specialties
    Health Care

    SEC Form SC 13D/A filed by Second Sight Medical Products Inc. (Amendment)

    SC 13D/A - SECOND SIGHT MEDICAL PRODUCTS INC (0001266806) (Subject)

    7/22/22 5:06:56 PM ET
    $EYES
    Industrial Specialties
    Health Care